TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02227537

Intervention type: DEVICE
Intervention: Providence Nighttime Bracing System
Description: Providence Nighttime Bracing System

Intervention type: DEVICE
Intervention: Providence Nighttime Bracing System
Description: The Providence brace is a polypropylene plastic, acrylic framed, system designed to apply corrective forces to scoliatic curves achieving correction or reduction of scoliosis.
Study: NCT00946465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10 Capsule (Sandoz)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)
Study: NCT04602390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANK-700
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANK-700
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANK-700
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANK-700
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANK-700
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) infusion
Study: NCT01082445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg, 1 tablet 3 times a day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04708405

Intervention type: OTHER
Intervention: Observation
Description: Follow up and observe under standard of care given
Study: NCT04063384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alcohol beverage
Description: Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: placebo beverage conditions.
Study: NCT04272177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision making with the used of patient decision aids
Description: PDA is used to explain choices of reversal drugs using SDM approach during consultation. The patients and medical staff explore the preferences with PDA and make decision together.
Study: NCT00840359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Application of Metvix 16% cream followed by exposure to daylight for 2.5 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Cryotherapy for 2 times 20 sec
Study: NCT01536691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Description: ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
Study: NCT02651896

Intervention type: RADIATION
Intervention: HypoIGRT
Description: Hypofractionated intensity modulated and image guided radiotherapy 60 Gy in 20 fractions over four weeks for the prostate gland to all groups.~For intermediate and high risk group: seminal vesicle will be included: 48 Gy in 20 fractions over 4 weeks (proximal third to half on physicians description).~Image guidance with cone beam CT will be mandatory before every treatment fraction.
Study: NCT02604069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Study: NCT01773278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidants
Description: Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidants
Description: Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidants
Description: Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholesterol
Description: Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels \> 100 mg/dl if possible

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholesterol
Description: Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels \> 100 mg/dl if possible

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholesterol
Description: Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels \> 100 mg/dl if possible
Study: NCT02235961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-0530
Description: Administered as single subcutaneous (s.c., under the skin) injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-0530
Description: Administered as single subcutaneous (s.c., under the skin) injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered as single subcutaneous (s.c., under the skin) injections.
Study: NCT03942276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Consists of 60 seconds sets of high-intensity exercises, characterized by heart rate\> 85% of maximal heart rate (HRmax), obtained through the formula (220-age), or by the Rated Perceived Exertion between 7 and 8 on the Borg scale, which ranges from 0 to 10. Of the 60 seconds of high intensity exercise, 30 seconds will be to get up and down a 16 cm step and 30 seconds of squats, with knee flexion greater than 90º, both at the highest possible speed. The recovery between sets is light walk for 60 seconds. If the volunteers do not reach the proposed intensity zone, they will be instructed to increase the number of squats and step ascents and descents.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training
Description: Consist of performing a 30 minute walk at 50% of reserve heart rate (HRR), calculated by (HRmax - HRmax) x% + HRmax. HRmax being obtained by means of the formula (220 - age).
Study: NCT02235961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered as single subcutaneous (s.c., under the skin) injections.
Study: NCT04316598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Sativa
Description: Subjects will receive a total of 4 inhaled doses of 20 mg of tetrahydrocannabinol (THC) in 3 days.~Cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing THC 22% and cannabidiol \<1%, supplied by Bedrocan®.~To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of Cannabis flos, equivalent to 20 mg of THC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis placebo
Description: Subjects will receive a total of 4 inhaled doses of cannabis placebo (THC \<0,2%) in 3 days.~Placebo cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing cannabinoids \<0.2%. To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of cannabis placebo.
Study: NCT01313000

Intervention type: PROCEDURE
Intervention: Autologous fat transfer
Description: Autologous fat transfer from abdomen to upper arms
Study: NCT03075657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone will be prescribed at dose of 2 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone and Ramelteon
Description: Ramelteon will be prescribed 8mg/day as an add-on therapy to Risperidone 2 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol will be prescribed at a dose of 4 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol and Ramelteon
Description: Ramelteon will be prescribed 8mg/day as an add-on therapy to Haloperidol 4 mg per day
Study: NCT02565082

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling - healthy volunteers
Description: Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling - sickle cell patients arm - stable condition
Description: Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling - sickle cell patients arm- exsanguinotransfusion needed
Description: Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling - sickle cell patients arm - vaso-occlusive crisis.
Description: Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
Study: NCT02611206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT
Description: rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT
Description: rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT
Description: rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS
Study: NCT01637025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxidized cellulose strip
Description: Single use, intra-operative application to the target bleeding site

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxidized regenerated cellulose strip
Description: A substance used to promote hemostasis (stops bleeding) based on oxidized regenerated cellulose
Study: NCT01017458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0773
Description: Three 25mg oral tablets MK0773 bid, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: testosterone enanthate
Description: intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: placebo oral tablet
Description: placebo oral tablet bid, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo oral tablet
Description: placebo oral tablet bid, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo injection
Description: placebo intramuscular injection q14d, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo injection
Description: placebo intramuscular injection q14d, for 12 weeks
Study: NCT02189395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH and regular insulin
Study: NCT03929146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Patients will receive a local injection of liposomal bupivacaine near the end of their shoulder arthroplasty operation.
Study: NCT02189395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glargine and humalog
Study: NCT01512784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)
Description: Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~First dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)
Description: Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~first dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms.
Study: NCT01428726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-KO-003
Description: NT-KO-003 is a coated tablet, administered once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-KO-003
Description: NT-KO-003 is a coated tablet, administered once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NT-KO-003
Description: NT-KO-003 is a coated tablet, administered once a day
Study: NCT04562025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 3 times of UC-MSCs (1\*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).
Study: NCT02281071

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laterally moved coronally advanced flap with microsurgical instruments and x2.5 loupe
Description: The recipient area for the laterally moved flap was prepared. When the flap was moved in the distal-mesial direction another short horizontal incision was performed at the most apical extension of this vertical incision. Once the mucogingival line was reached, flap elevation was continued split-thickness. Flap elevation was terminated when it was possible to passively move the flap laterally above the exposed root. Flap was sutured.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laterally moved coronally advanced flap with microsurgical instruments and x2.5 loupe
Description: The recipient area for the laterally moved flap was prepared. When the flap was moved in the distal-mesial direction another short horizontal incision was performed at the most apical extension of this vertical incision. Once the mucogingival line was reached, flap elevation was continued split-thickness. Flap elevation was terminated when it was possible to passively move the flap laterally above the exposed root. Flap was sutured.
Study: NCT04703725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Care
Description: 1. First Follow-Up: One of the implementation of the module~2. Second Follow-up: Implementation of the second module; Breathing Exercises and EFT~3. Third Follow-up: Emotional preparation about egg pick up process, individual application of coping methods~4. Fourth Follow-up: Implementation of the second module; Briefing about Breathing Exercises and EFT embryo transfer process~5. Fifth Follow-up: Implementation of the second module; Breathing Exercises and EFT~6. Sixth Follow-up: Individual application of coping methods until the learning process of pregnancy test result~7. Seventh Follow-up: Providing information about the first periods of pregnancy after treatment resulting in pregnancy and providing information about the psychosocial problems that may be encountered. Identifying psychosocial problems that may be encountered after unsuccessful treatment and individual application of coping methods to help cope.
Study: NCT02106169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education group
Study: NCT00505505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (Actrapid)
Description: 50 UI Actrapid diluted in 50 ml of saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (Actrapid)
Description: 50 UI Actrapid diluted in 50 ml of saline
Study: NCT02598193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.
Study: NCT04698564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].
Study: NCT02934269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90006
Study: NCT01669044

Intervention type: DRUG
Intervention: dexmedetomidine
Description: dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.

Intervention type: DRUG
Intervention: propofol
Description: propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
Study: NCT03472833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose
Description: Patients will receive a high dose - 180.000 I.U. (1 drop equals 400 I.U.) of Vitamin D3 orally on day 1, and then 4000 I.U. for 60 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose
Description: Patients will receive a standard dose - 800 I.U. (equals 2 drops) of Vitamin D3 orally for 60 days
Study: NCT02947373

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperpolarized Pyruvate
Description: Hyperpolarized Pyruvate
Study: NCT03940326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam with initial dose of 500 mg per 12 hours which will be increased 500 mg/week to target dose of 2000 mg/day and the dose could be increased to 3000 mg/day if seizures recurred

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: Sodium valproate with initial dose of 500 mg/day which will be increased 500 mg/week to target dose of 1500 mg/day and the dose could be increased to 2000 mg/d if seizures recurred.
Study: NCT04262869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT02905240

Intervention type: DEVICE
Group type: OTHER
Intervention: Saline
Description: single intra-articular injection
Study: NCT00482768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: Clinics in the experimental arm will meet with a trained facilitator to work on change strategies that will improve risk factors for diabetes complications.
Study: NCT00873392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Description: Steps of 5 mg until 20 mg Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual drug treatment of Parkinson's disease
Description: Usual drug treatment of Parkinson's disease